PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma
This study is currently closed to enrollment.
HEALTHY PARTICIPANTS: No
ISTR1320, A Phase 1, Open-label, Single-arm Study Evaluating the Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma (PVSRIPO CPI rGBM 101)
The purpose of this study is to determine the tolerance, safety and efficacy of a single dose of PVSRIPO followed by pembrolizumab is in adults diagnosed with a recurrent glioblastoma (rGBM). PVSRIPO and Pembrolizumab are investigational (experimental) drugs. Pembrolizumab works by helping your immune system recognize and fight cancer cells.
Who Can Participate
Patients 18 years of age or older 18 years of age who have been histologically confirmed with recurrent, supratentorial glioblastoma; progression of primary glioblastoma or transformation from a lower grade to a higher grade of glioblastoma may be eligible for this study.